SCHEMBL4034659

SCHEMBL4034659

COc1ccc(C2(C(C(=O)NC3CCCCC3)C3CCCCC3)Nc3ccc(F)cc3N2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
EPHX2 P34913 2/20 0.42
TSHR P16473 1/20 0.42
EPHX1 P07099 1/20 0.42
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
MAPK1 P28482 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 3/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP2C9 P11712 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039833 0.94 NPC1 (0.42) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4042532 0.94 NPC1 (0.42) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4037444 0.87 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4045000 0.87 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4038480 0.87 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4036972 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2EPHX1ALDH1A1
SCHEMBL4036796 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2EPHX1ALDH1A1
SCHEMBL3648565 0.87 MAPT (0.44) NPC1RAB9ASMN1; SMN2EPHX2TSHR
SCHEMBL4035047 0.87 MEN1 (0.45) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL4041388 0.84 NR1H4 (0.40) NPC1RAB9ASMN1; SMN2EPHX2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed